Daxor (DXR) Competitors

$10.95 +0.45 (+4.29%)

Closing price 03:54 PM Eastern

Extended Trading

$11.29 +0.34 (+3.11%)

As of 04:10 PM Eastern

DXR vs. INGN, KRMD, CVRX, PDEX, and STEX

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include Inogen (INGN), KORU Medical Systems (KRMD), CVRx (CVRX), Pro-Dex (PDEX), and Biosig Technologies (STEX). These companies are all part of the "medical equipment" industry.

How does Daxor compare to Inogen?

Daxor (NASDAQ:DXR) and Inogen (NASDAQ:INGN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Daxor has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Inogen has a beta of 1.64, suggesting that its share price is 64% more volatile than the broader market.

Daxor has higher earnings, but lower revenue than Inogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Inogen	$348.67M	0.53	-$22.75M	-$0.91	N/A

In the previous week, Inogen had 8 more articles in the media than Daxor. MarketBeat recorded 9 mentions for Inogen and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat Inogen's score of -0.14 indicating that Daxor is being referred to more favorably in the media.

Company	Overall Sentiment
Daxor	Very Positive
Inogen	Neutral

Daxor has a net margin of 0.00% compared to Inogen's net margin of -7.08%. Daxor's return on equity of 0.00% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Inogen	-7.08%	-12.90%	-8.27%

1.3% of Daxor shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 59.5% of Daxor shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inogen has a consensus target price of $13.00, suggesting a potential upside of 91.18%. Given Inogen's stronger consensus rating and higher possible upside, analysts plainly believe Inogen is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inogen	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Inogen beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to KORU Medical Systems?

Daxor (NASDAQ:DXR) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Daxor has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, KORU Medical Systems has a beta of 0.43, suggesting that its share price is 57% less volatile than the broader market.

Daxor has higher earnings, but lower revenue than KORU Medical Systems.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
KORU Medical Systems	$41.13M	4.44	-$2.64M	-$0.05	N/A

In the previous week, KORU Medical Systems had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for KORU Medical Systems and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat KORU Medical Systems' score of 0.34 indicating that Daxor is being referred to more favorably in the media.

Company	Overall Sentiment
Daxor	Very Positive
KORU Medical Systems	Neutral

Daxor has a net margin of 0.00% compared to KORU Medical Systems' net margin of -5.27%. Daxor's return on equity of 0.00% beat KORU Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
KORU Medical Systems	-5.27%	-13.61%	-8.33%

1.3% of Daxor shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 59.5% of Daxor shares are held by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

KORU Medical Systems has a consensus target price of $7.25, suggesting a potential upside of 82.16%. Given KORU Medical Systems' stronger consensus rating and higher possible upside, analysts plainly believe KORU Medical Systems is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
KORU Medical Systems	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

KORU Medical Systems beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to CVRx?

CVRx (NASDAQ:CVRX) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

75.3% of CVRx shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 13.9% of CVRx shares are owned by company insiders. Comparatively, 59.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CVRx currently has a consensus target price of $11.50, suggesting a potential upside of 100.35%. Given CVRx's stronger consensus rating and higher probable upside, analysts clearly believe CVRx is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

CVRx has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Daxor has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Daxor has lower revenue, but higher earnings than CVRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.69	-$53.31M	-$2.02	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

In the previous week, CVRx had 14 more articles in the media than Daxor. MarketBeat recorded 15 mentions for CVRx and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat CVRx's score of 0.43 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
CVRx	Neutral
Daxor	Very Positive

Daxor has a net margin of 0.00% compared to CVRx's net margin of -89.14%. Daxor's return on equity of 0.00% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Daxor	N/A	N/A	N/A

Summary

CVRx beats Daxor on 7 of the 12 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Pro-Dex (NASDAQ:PDEX) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 45.9% of Pro-Dex shares are owned by company insiders. Comparatively, 59.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pro-Dex currently has a consensus target price of $70.00, suggesting a potential upside of 19.35%. Given Pro-Dex's higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Pro-Dex has a beta of -0.12, suggesting that its stock price is 112% less volatile than the broader market. Comparatively, Daxor has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$66.59M	2.81	$8.98M	$3.62	16.20
Daxor	N/A	N/A	N/A	N/A	N/A

In the previous week, Pro-Dex had 9 more articles in the media than Daxor. MarketBeat recorded 10 mentions for Pro-Dex and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat Pro-Dex's score of 1.28 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
Pro-Dex	Positive
Daxor	Very Positive

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pro-Dex	16.08%	22.78%	14.30%
Daxor	N/A	N/A	N/A

Summary

Pro-Dex beats Daxor on 7 of the 10 factors compared between the two stocks.

How does Daxor compare to Biosig Technologies?

Biosig Technologies (NASDAQ:STEX) and Daxor (NASDAQ:DXR) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Daxor's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-1,476.78%	-428.30%
Daxor	N/A	N/A	N/A

Biosig Technologies has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market. Comparatively, Daxor has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 59.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Biosig Technologies currently has a consensus target price of $9.00, suggesting a potential upside of 841.42%. Given Biosig Technologies' higher possible upside, equities research analysts clearly believe Biosig Technologies is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has lower revenue, but higher earnings than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,329.25	-$462.77M	-$9.58	N/A
Daxor	N/A	N/A	N/A	N/A	N/A

In the previous week, Biosig Technologies had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Biosig Technologies and 1 mentions for Daxor. Daxor's average media sentiment score of 1.89 beat Biosig Technologies' score of 0.81 indicating that Daxor is being referred to more favorably in the news media.

Company	Overall Sentiment
Biosig Technologies	Positive
Daxor	Very Positive

Summary

Biosig Technologies and Daxor tied by winning 5 of the 10 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.91M	$5.58B	$6.34B	$12.38B
Dividend Yield	N/A	1.56%	2.80%	5.35%
P/E Ratio	N/A	34.69	20.90	25.61
Price / Sales	N/A	22.78	549.93	78.79
Price / Cash	N/A	16.43	43.26	56.33
Price / Book	N/A	3.15	9.93	6.96
Net Income	N/A	$218.81M	$3.55B	$333.52M
7 Day Performance	13.77%	-0.05%	-0.33%	0.45%
1 Month Performance	16.74%	3.72%	1.34%	4.06%
1 Year Performance	50.00%	20.19%	41.10%	36.24%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	2.6134 of 5 stars	$10.95 +4.3%	N/A	+43.0%	$52.91M	N/A	N/A	37	Gap Up
INGN Inogen	2.5343 of 5 stars	$7.19 +1.1%	$13.00 +80.8%	+10.9%	$194.28M	$348.67M	N/A	1,030	Earnings Report
KRMD KORU Medical Systems	3.2756 of 5 stars	$4.44 +10.7%	$7.25 +63.3%	+19.9%	$186.91M	$41.13M	N/A	80	Gap Up High Trading Volume
CVRX CVRx	3.373 of 5 stars	$7.32 +3.5%	$10.50 +43.4%	-4.0%	$186.87M	$56.65M	N/A	160	News Coverage Earnings Report
PDEX Pro-Dex	2.4958 of 5 stars	$57.42 -1.8%	$56.00 -2.5%	+35.2%	$186.78M	$74.64M	15.86	140	News Coverage Positive News Analyst Forecast Analyst Revision Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors